Cytokine storm and the prospects for immunotherapy with COVID-19
Author:
Open Access
- 11 May 2020
- journal article
- research article
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 87 (7) , 389-393
Abstract
Knowledge about the pathobiology of SARS-COV-2 as it interacts with immune defenses is limited. SARS-COV-2 is spread by droplets that come into contact with mucous membranes. COVID-19 is characterized by 3 stages: asymptomatic-paucisymptomatic incubation, nonsevere symptomatic illness for 80% of those infected, and severe respiratory illness. A syndrome characterized by hypercytokinemic inflammation referred to as a “cytokine storm” can occur in patients with advanced disease. Effective antiviral agents that can prevent viral infection in exposed individuals are needed.Keywords
This publication has 14 references indexed in Scilit:
- Potential Effects of Coronaviruses on the Cardiovascular SystemJAMA Cardiology, 2020
- The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like DiseaseAutoimmunity Reviews, 2020
- Understanding COVID-19: what does viral RNA load really mean?The Lancet Infectious Diseases, 2020
- The immunology of COVID-19: is immune modulation an option for treatment?The Lancet Rheumatology, 2020
- Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapyJournal of Autoimmunity, 2020
- COVID-19: consider cytokine storm syndromes and immunosuppressionThe Lancet, 2020
- Coronavirus infections and immune responsesJournal of Medical Virology, 2020
- Management of cytokine release syndrome related to CAR-T cell therapyFrontiers of Medicine, 2019
- Macrophage activation syndrome in the era of biologic therapyNature Reviews Rheumatology, 2016
- IL-6 biology: implications for clinical targeting in rheumatic diseaseNature Reviews Rheumatology, 2014